Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer

Oncologist

Volumn 4, Issue 5, 1999, Pages 408-416

  Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

NSCLC; Paclitaxel

Indexed keywords

PACLITAXEL;

ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MYALGIA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0032707828     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-5-408     Document Type: Article

References (16)

1. Wani MC, Taylor HL, Wall ME et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327.
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667.
3. Schiff PB, Horwitz SB. Taxol stabilizes microtubule in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-1565.
4. Rowinsky EK, Casenave LA, Donehower RC. Taxol: a novel investigational antimicrotubular agent. J Natl Cancer Inst 1990;82:1247-1249.
5. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
6. Rowinsky EK, Donehower RC. Paclitaxel. In: PPO Updates, Principles & Practice of Oncology 1994;8:1-16.
7. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-8.
8. Bonomi P, Kim K, Kugler J et al. Comparison of survival for stage IIIB versus stage IV non-small cell lung cancer (NSCLC) patients with etoposide-cisplatin versus taxol-cisplatin: an Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 1997;16:454a.
9. Henderson IC, Berry D, Demetri G et al. Improved disease-free (DPS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer. Proc Am Soc Clin Oncol 1998;17:101a.
10. Flehinger BJ, Kimmel M, Polyak T et al. Screening for lung cancer. Cancer 1993;72:1573-1580.
11. Parker SL, Tong T, Belden S et al. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
12. Bonomi P, Kim K, Chang A et al. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 1996;15:382a.
13. Belani CP, Natale RB, Lee JS et al. Randomized phase III trial comparing cisplatin/etopside versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;17:455a.
14. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-195.
15. Venook AP, Egorin MJ, Rosner GL et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998;16:1811-1819.
16. Socinski MA, Mudd PN Jr, Radomski KM et al. Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. Anti-Cancer Drugs 1998;9:611-619.